Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nalfurafine orally disintegrating tablet for refractory pruritus in hemodialysis patients
CTR20201271Phase 3Completed
- Sponsor
- Toray Industries
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of nalfurafine in chronic kidney disease (CKD), sponsored by Toray Industries. Started Jul 2020; status: completed.
02
Drugs
nalfurafine
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on CTR20201271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201271.